New trial
Spotlight
Phase I MB-CART19.1 (CD19 CAR-T) for CNS lymphoma
- Trial ID
- NCT07137494 on ClinicalTrials.gov
- Cancer type
- CNS Lymphoma (including DLBCL)
- Stage of research
- Exploratory
- Location
- New York, NY
- Published in
- New in Oncology - Sept 12, 2025
MSK identifies the maximum safe dose of on-site–manufactured CD19 CAR-T for primary/secondary CNS lymphoma (incl. DLBCL), using CliniMACS Prodigy (Miltenyi Biomedicine), leukapheresis, conditioning chemo, and infusion with serial CSF/blood sampling. HD-MTX ± rituximab and transplant can fail in CNS disease; adapting CAR-T to CNS aims for deeper remissions where systemic options falter. Neurotoxicity monitoring and early response signals will drive next steps.
More in lymphoma
-
Trial result · Oct 22, 2026 · NCT04245839
Liso-cel (CD19 CAR-T) Delivers 100% CR/ORR With Minimal CRS/Neurotoxicity in Japanese R/R FL -
Trial result · Oct 22, 2026 · NCT05800366
Glofitamab (CD3×CD20) + pola-R-CHP (CD79b ADC + anti-CD20 chemoimmunotherapy) drives 95% CR and 95% 24‑mo PFS in high-risk 1L DLBCL -
Trial result · Oct 15, 2026 · NCT03618550
Pembrolizumab-GVD followed by autologous transplantation shows 91% five-year PFS in relapsed/refractory classical Hodgkin lymphoma -
Trial result · Oct 15, 2026 · NCT03598608
Favezelimab (anti–LAG-3) + pembrolizumab (PD-1) reports 83% ORR in PD-1–naive R/R cHL; development discontinued -
Trial result · Oct 1, 2026
Mosunetuzumab (CD20xCD3 bispecific) + response-adapted polatuzumab vedotin (CD79b ADC) drives 86% PET-CR and 89% 2y PFS in untreated indolent NHL